Immunogenicity remodeling in hepatocellular carcinoma: mechanisms and translational strategies
Therapeutic Advances in Medical Oncology · 2026-07 · 18
DOI: 10.1177/17588359261461753 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Therapeutic Advances in Medical Oncology, online erschienen am 08.07.2026. Verfasst von Yali Li und 8 weiteren Autor:innen. Beteiligte Einrichtung: The Second Hospital and Clinical Medical School, Lanzhou University, Lanzhou, China. Die Arbeit nennt 99 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Natural Science Foundation of China, Key Project of Science and Technology in Gansu Province, Major Scientific Research Project for Scientific and Technological Innovation in the Health Industry of Gansu Province.
Abstract (Originalsprache)
Hepatocellular carcinoma (HCC) continues to pose a significant global health challenge. In recent years, immunotherapy has emerged as a critical component of HCC treatment, demonstrating encouraging outcomes in a subset of patients. Nevertheless, the overall response rate to immune checkpoint inhibitors (ICIs) remains modest. Deficient immunogenicity and the consequent failure to adequately activate antitumor immunity are widely regarded as central constraints on immunotherapy efficacy. Unlike previous reviews focusing on immune escape or clinical outcomes, this review centers on tumor immunogenicity as the key determinant of immunotherapy response. We systematically summarize the major mechanisms regulating HCC immunogenicity and outline current strategies to enhance and remodel it. By conceptualizing immunogenicity as the principal determinant of immunotherapy efficacy, we propose a unified framework centered on immunogenicity that integrates intrinsic tumor characteristics, microenvironmental regulation, and diverse therapeutic interventions. Within this framework, we highlight representative immunogenicity‑enhancing strategies, including epigenetic restoration of antigen presentation capacity, induction of immunogenic cell death through local or systemic therapies, and vaccine‑based approaches aimed at amplifying antitumor immunity. Collectively, this review offers a systematic and coherent perspective on immune tolerance in HCC through the lens of immunogenicity remodeling, thereby providing a conceptual foundation for the rational design of future immunotherapy strategies.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- The Second Hospital and Clinical Medical School, Lanzhou University, Lanzhou, China.
- The Second Hospital and Clinical Medical School, Lanzhou University, Lanzhou 730030, Gansu, China.
- Cancer Center, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200080, China.
ORCID-Profile: Hao Chen
Förderung
- National Natural Science Foundation of China
- Key Project of Science and Technology in Gansu Province
- Major Scientific Research Project for Scientific and Technological Innovation in the Health Industry of Gansu Province
Zitieren
APA
Li, Y., Yan, Y., Ma, J., Liao, L., Liu, J., Ma, J., Qi, Y., Han, Z., & Chen, H. (2026). Immunogenicity remodeling in hepatocellular carcinoma: mechanisms and translational strategies. Therapeutic Advances in Medical Oncology, 18. https://doi.org/10.1177/17588359261461753
Vancouver
Li Y, Yan Y, Ma J, Liao L, Liu J, Ma J, et al. Immunogenicity remodeling in hepatocellular carcinoma: mechanisms and translational strategies. Therapeutic Advances in Medical Oncology. 2026;18. doi:10.1177/17588359261461753
BibTeX
@article{Li2026,
author = {Li, Yali and Yan, Ying and Ma, Jingwei and Liao, Lingzhi and Liu, Jing and Ma, Jiahui and Qi, Yile and Han, Zhijian and Chen, Hao},
title = {Immunogenicity remodeling in hepatocellular carcinoma: mechanisms and translational strategies},
journal = {Therapeutic Advances in Medical Oncology},
year = {2026},
volume = {18},
doi = {10.1177/17588359261461753}
}
EUVIMED